Advertisement

Acta Diabetologica

, 45:131 | Cite as

Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications

  • Elena Beltramo
  • Elena Berrone
  • Sonia Tarallo
  • Massimo Porta
Review Article

Abstract

Thiamine (vitamin B1) is an essential cofactor in most organisms and is required at several stages of anabolic and catabolic intermediary metabolism, such as intracellular glucose metabolism, and is also a modulator of neuronal and neuro-muscular transmission. Lack of thiamine or defects in its intracellular transport can cause a number of severe disorders. Thiamine acts as a coenzyme for transketolase (TK) and for the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes, enzymes which play a fundamental role for intracellular glucose metabolism. In particular, TK is able to shift excess fructose-6-phosphate and glycerhaldeyde-3-phosphate from glycolysis into the pentose-phosphate shunt, thus eliminating these potentially damaging metabolites from the cytosol. Diabetes might be considered a thiamine-deficient state, if not in absolute terms at least relative to the increased requirements deriving from accelerated and amplified glucose metabolism in non-insulin dependent tissues that, like the vessel wall, are prone to complications. A thiamine/TK activity deficiency has been described in diabetic patients, the correction of which by thiamine and/or its lipophilic derivative, benfotiamine, has been demonstrated in vitro to counteract the damaging effects of hyperglycaemia on vascular cells. Little is known, however, on the positive effects of thiamine/benfotiamine administration in diabetic patients, apart from the possible amelioration of neuropathic symptoms. Clinical trials on diabetic patients would be necessary to test this vitamin as a potential and inexpensive approach to the prevention and/or treatment of diabetic vascular complications.

Keywords

Thiamine Benfotiamine Diabetes Diabetic complications High glucose 

References

  1. 1.
    Jansen B, Donath W (1926) Geneeskundig Tijdschrift voor Nederlandsch-Indie 66:1–2 (Reprinted as (1982) The isolation of the anti beri beri vitamin. Nutr Rev 40:53–55)Google Scholar
  2. 2.
    Frank RAW, Leeper FJ, Luisi BF (2007) Structure, mechanism and catalytic duality of thiamine-dependent enzymes. Cell Mol Life Sci 64:892–905PubMedGoogle Scholar
  3. 3.
    Bender DA (1999) Optimum nutrition: thiamin, biotin and pantothenate. Proc Nutr Soc 58:427–433PubMedGoogle Scholar
  4. 4.
    Stryer L (1988) Biochemistry. Freeman WH and Company, New YorkGoogle Scholar
  5. 5.
    Harper C (1979) Wernicke’s encephalopathy, a more common disease than realised (a neuropathological study of 51 cases). J Neurol Neurosurg Psychol 42:226–231Google Scholar
  6. 6.
    Neufeld EJ, Fleming JC, Tartaglini E, Steinkamp MP (2001) Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. Blood Cells Mol Dis 27:135–138PubMedGoogle Scholar
  7. 7.
    Thomson AD (2000) Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke–Korsakoff syndrome. Alcohol Alcohol Suppl 35:2–7PubMedGoogle Scholar
  8. 8.
    Abbas ZG, Swai AB (1997) Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East Afr Med J 74:803–808PubMedGoogle Scholar
  9. 9.
    Wu S, Ren J (2006) Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 394:158–162PubMedGoogle Scholar
  10. 10.
    Hoyumpa AM Jr, Strickland R, Sheehan JJ, Yarborough G, Nichols S (1982) Dual system of intestinal thiamine transport in humans. J Lab Clin Med 99:701–708PubMedGoogle Scholar
  11. 11.
    Rindi G (1984) Thiamine absorption by small intestine. Acta Vitaminol Enzymol 6:47–55PubMedGoogle Scholar
  12. 12.
    Rindi G, Lafarenza U (2000) Thiamine intestinal transport and related issues: recent aspects. PSEBM 224:246–255Google Scholar
  13. 13.
    Rindi G, Ferrari G (1997) Thiamine transport by human intestine in vitro. Experientia 33:211–213Google Scholar
  14. 14.
    Lafarenza U, Patrini C, Alvisi C, Faelli A, Licandro A, Rindi G (1997) Thiamine uptake in human intestinal biopsy specimen, including observations from a patient with acute thiamine deficiency. Am J Clin Nutr 66:320–326Google Scholar
  15. 15.
    Patrini C, Lafarenza U, Gastaldi G, Verri A, Ferrari G, Rindi G (1996) Effects of insulin on thiamine intestinal transport in rat everted jejunal sacs. J Physiol (Lond) 493:100S–101SGoogle Scholar
  16. 16.
    Lafarenza U, Gastaldi G, Verri A, Rindi G (1995) Effects of thyroid hormone and insulin on thiamine intestinal transport in vitro. Ital J Gastroenterol 27:129Google Scholar
  17. 17.
    Fujimara M, Sasakawa S, Itokawa Y, Ikeda K (1964) Affinity of thiamine propyl disulfide-S35 to organs. J Vitaminol (Kyoto) 10:79–87Google Scholar
  18. 18.
    Fujimara M (1976) Allithiamine and its properties. J Nutr Sci Vitaminol (Tokyo) 22(Suppl):57–62Google Scholar
  19. 19.
    Baker H, Frank O (1976) Absorption, utilization and clinical effectiveness of allithiamines compared to water-soluble thiamines. J Nutr Sci Vitaminol (Tokyo) 22(Suppl):63–68Google Scholar
  20. 20.
    Greb A, Bitsch R (1998) Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 36:216–221PubMedGoogle Scholar
  21. 21.
    Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH (1997) Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Pharmacol 52:319–320Google Scholar
  22. 22.
    Loew D (1996) Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 34:47–50PubMedGoogle Scholar
  23. 23.
    Brownlee M (1994) Glycation and diabetic complications. Diabetes 43:836–841PubMedGoogle Scholar
  24. 24.
    Schenk G, Duggleby RG, Nixon PF (1998) Properties and functions of the thiamine diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol 30:1297–1318PubMedGoogle Scholar
  25. 25.
    Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120PubMedGoogle Scholar
  26. 26.
    Thornalley PJ, Jahan I, Ng R (2001) Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. J Biochem 129:543–549PubMedGoogle Scholar
  27. 27.
    Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299PubMedGoogle Scholar
  28. 28.
    Nixon PF, Price J, Norman-Hick M, Williams GM, Kerr RA (1990) The relationship between erythrocyte transketolase activity and the “TPP effect” in Wernicke’s encephalopathy and other thiamine deficiency states. Clin Chim Acta 192:89–98PubMedGoogle Scholar
  29. 29.
    Horwitt MK, Kreisler O (1949) The determination of early thiamine deficient states by estimation of blood lactate and pyruvate after glucose administration and exercise. J Nutr 37:411–427PubMedGoogle Scholar
  30. 30.
    Butterworth RF, Kril JJ, Harper CG (1993) Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke–Korsakoff syndrome. Alcohol Clin Exp Res 17:1084–1088PubMedGoogle Scholar
  31. 31.
    DCCT: The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986Google Scholar
  32. 32.
    UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853Google Scholar
  33. 33.
    Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80–89PubMedGoogle Scholar
  34. 34.
    Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P (1995) Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96:1802–1814PubMedGoogle Scholar
  35. 35.
    Giardino I, Edelstein D, Brownlee M (1996) Bcl-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 97:1422–1428PubMedGoogle Scholar
  36. 36.
    Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int 58:S26–S30Google Scholar
  37. 37.
    Brignardello E, Beltramo E, Molinatti PA, Aragno M, Gatto V, Tamagno E, Danni O, Porta M, Boccuzzi G (1998) Dehydroepiandrosterone protects bovine retinal capillary pericytes against glucose toxicity. J Endocrinol 158:21–26PubMedGoogle Scholar
  38. 38.
    Podestà F, Romeo G, Liu WH, Krajewski S, Reed JC, Gerhardinger C, Lorenzi M (2000) Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 156:1025–1032PubMedGoogle Scholar
  39. 39.
    Beltramo E, Berrone E, Buttiglieri S, Porta M (2004) Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 20:330–336PubMedGoogle Scholar
  40. 40.
    Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa P, Kaistura J (2001) Hyperglycemia activates p53 and p53-regulated denes leading to myocyte cell death. Diabetes 50:2363–2375PubMedGoogle Scholar
  41. 41.
    Kang BP, Frencher S, Reddy V, Kessler A, Malhotra A, Meggs LG (2003) High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. Am J Physiol Renal Physiol 284:F455–F466PubMedGoogle Scholar
  42. 42.
    Vincent AM, McLean LL, Backus C, Feldman EL (2005) Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 19:638–640PubMedGoogle Scholar
  43. 43.
    Khera T, Martin J, Riley S, Steadman R, Phillips AO (2006) Glucose enhances mesangial cell apoptosis. Lab Invest 86:566–577PubMedGoogle Scholar
  44. 44.
    Sustzak K, Raff AC, Schiffer M, Böttinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225–231Google Scholar
  45. 45.
    Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappa B induced by diabetes and high glucose regulates a pro-apoptotic program in retinal pericytes. Diabetes 51:2604–2611Google Scholar
  46. 46.
    Li W, Liu X, Yanoff M, Cohen S, Ye X (1996) Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39:537–547PubMedGoogle Scholar
  47. 47.
    Li W, Liu X, He Z, Yanoff M, Jian B, Ye X (1998) Expression of apoptosis regulatory genes by retinal pericytes after rapid glucose reduction. IOVS 39:1535–1543Google Scholar
  48. 48.
    Ihnat MA, Thorpe JE, Kamat CD, Szabó C, Green DE, Warnke LA, Lacza Z, Cselenyák A, Ross K, Shakir S, Piconi L, Kaltreider RC, Ceriello A (2007) Reactive oxygen species mediate a cellular “memory” of high glucose stress signalling. Diabetologia 50:1523–1531PubMedGoogle Scholar
  49. 49.
    Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M (1988) Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 82:735–738PubMedGoogle Scholar
  50. 50.
    Roy S, Sala R, Cagliero E, Lorenzi M (1990) Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci USA 87:404–408PubMedGoogle Scholar
  51. 51.
    Risso A, Mercuri F, Quagliaro L, Damante G, Ceriello A (2001) Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 281:E924–E930PubMedGoogle Scholar
  52. 52.
    Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A (2003) Intermittent high glucose enhances apoptosis relate to oxidative stress in human umbilical vein endothelial cells. Diabetes 52:2795–2804PubMedGoogle Scholar
  53. 53.
    Piconi L, Quagliaro L, Assaloni R, Da Ros R, Maier A, Zuodar G, Ceriello A (2006) Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diab Met Res Rev 22:198–203Google Scholar
  54. 54.
    Kowluru RA, Abbas SN, Odenbach S (2004) Reversal of hyperglycemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats. J Diabet Complications 18:282–288Google Scholar
  55. 55.
    Bonora E, Muggeo M (2001) Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44:2107–2114PubMedGoogle Scholar
  56. 56.
    Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(suppl.2):B21–B29PubMedGoogle Scholar
  57. 57.
    Van Ballegooie E, Hooymans JM, Timmerman Z, Reitsma WD, Sluiter WJ, Schweitzer NM, Doorenbos H (1984) Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion. Diabetes Care 7:236–242PubMedGoogle Scholar
  58. 58.
    Dandona P, Bolger JP, Boag F, Fonesca V, Abrams JD (1985) Rapid development and progression of proliferative retinopathy after strict diabetic control. BMJ 290:885–896Google Scholar
  59. 59.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenages O (1985) Rapid tightening of blood glucose levels leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus. BMJ 290:811–815PubMedGoogle Scholar
  60. 60.
    Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycaemic control. Diabetes 36:808–812PubMedGoogle Scholar
  61. 61.
    Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, Van Den Enden M, Kilo C, Tilton RG (1993) Hyperglycemic pseudoypoxia and diabetic complications. Diabetes 42:801–813PubMedGoogle Scholar
  62. 62.
    Lee AY, Chung SS (1999) Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13:23–30PubMedGoogle Scholar
  63. 63.
    Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedGoogle Scholar
  64. 64.
    Engerman RL, Kern TS, Larson ME (1994) Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 37:141–144PubMedGoogle Scholar
  65. 65.
    Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40:405–412PubMedGoogle Scholar
  66. 66.
    Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 94:110–117PubMedGoogle Scholar
  67. 67.
    Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC (1990) Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 39:807–814PubMedGoogle Scholar
  68. 68.
    Beltramo E, Pomero F, Allione A, D’Alù F, Ponte E, Porta M (2002) Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 45:416–419PubMedGoogle Scholar
  69. 69.
    Beltramo E, Buttiglieri S, Pomero F, Allione A, D’Alù F, Ponte E, Porta M (2003) A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia 46:409–415PubMedGoogle Scholar
  70. 70.
    Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ (1992) Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89:2873–2877PubMedGoogle Scholar
  71. 71.
    Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395–1403PubMedGoogle Scholar
  72. 72.
    Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174:931–939PubMedGoogle Scholar
  73. 73.
    Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555–11558PubMedGoogle Scholar
  74. 74.
    Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866PubMedGoogle Scholar
  75. 75.
    Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100:115–126PubMedGoogle Scholar
  76. 76.
    Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790PubMedGoogle Scholar
  77. 77.
    Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728–731PubMedGoogle Scholar
  78. 78.
    Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R (2000) Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439–447PubMedGoogle Scholar
  79. 79.
    Schleicher ED, Weigert C (2000) Role of the hexosamine biosyntetic pathway in diabetic nephropaty. Kidney Int 77:S13–S18Google Scholar
  80. 80.
    Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222–12226PubMedGoogle Scholar
  81. 81.
    DeRubertis FR, Craven PA, Melhem MF, Salah EM (2004) Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 53:762–768PubMedGoogle Scholar
  82. 82.
    Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 108:341–1057Google Scholar
  83. 83.
    La Selva M, Beltramo E, Pagnozzi F, Bena E, Molinatti PA, Molinatti GM, Porta M (1996) Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 39:1263–1268PubMedGoogle Scholar
  84. 84.
    Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophis Res Commun 220:113–119Google Scholar
  85. 85.
    Thornalley PJ, Jahan I, Ng R (2001) Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cells during hyperglycaemia by thiamine in vitro. Jpn J Biochem 129:543–549Google Scholar
  86. 86.
    Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M (2001) Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 38:135–138PubMedGoogle Scholar
  87. 87.
    Bakker SJ, Heine RJ, Gans RO (1997) Thiamine may indirectly act as an antioxidant. Diabetologia 40:741–742PubMedGoogle Scholar
  88. 88.
    Hsu GM, Chow BF (1960) Effect of thiamine deficiency on glutathione contents of erythrocytes and tissues in the rat. Proc Soc Exp Biol Med 104:178–180PubMedGoogle Scholar
  89. 89.
    Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129–146PubMedGoogle Scholar
  90. 90.
    Berrone E, Beltramo E, Solimine C, Ape AU, Porta M (2006) Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281:9307–9313PubMedGoogle Scholar
  91. 91.
    Ascher E, Gade PV, Hingorani A, Puthukkeril S, Kallakuri S, Scheinman M, Jacob T (2001) Thiamine reverses hyperglycemia-induced dysfunctions in cultured endothelial cells. Surgery 130:851–858PubMedGoogle Scholar
  92. 92.
    Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, Campesi I, Invernici G, Spillmann F, Ward K, Madeddu P (2006) Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 49:405–420PubMedGoogle Scholar
  93. 93.
    Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, Fukamizu A, Lauro R, Federici M (2006) Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 55:2231–2237PubMedGoogle Scholar
  94. 94.
    Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Köpcke W, Sauerland C, Bretzel RG, Federlin KF (2001) Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 109:330–336PubMedGoogle Scholar
  95. 95.
    Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J (2006) High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 100:150–156PubMedGoogle Scholar
  96. 96.
    Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ (2004) High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47:2235–2246PubMedGoogle Scholar
  97. 97.
    Hilbig R, Rahmann H (1998) Comparative autoradiographic investigations on the tissue distribution of benfotiamine versus thiamine in mice. Arzneimittelforschung 48:461–468PubMedGoogle Scholar
  98. 98.
    Yenilmez A, Ozçifçi M, Aydin Y, Turgut M, Uzuner K, Erkul A (2006) Protective effect of high-dose thiamine (B1) on rat detrusor contractility in streptozotocin-induced diabetes mellitus. Acta Diabetol 43:103–108PubMedGoogle Scholar
  99. 99.
    Frank T, Bitsch R, Maiwald J, Stein G (2000) High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur J Clin Pharmacol 56:251–257PubMedGoogle Scholar
  100. 100.
    Woelk H, Lehrl S, Bitsch R, Kopcke W (1998) Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAPI Study). Alcohol Alcohol 33:631–638PubMedGoogle Scholar
  101. 101.
    Stracke H, Lindemann A, Federlin K (1996) A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 104:311–316PubMedCrossRefGoogle Scholar
  102. 102.
    Haupt E, Ledermann H, Kopcke W (2005) Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 43:71–77PubMedGoogle Scholar
  103. 103.
    Saito N, Kimura M, Kuchiba A, Itokawa Y (1987) Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol 33:421–430PubMedGoogle Scholar
  104. 104.
    Valerio G, Franzese A, Poggi V, Patrini C, Laforenza U, Tenore A (1999) Lipophilic thiamine treatment in long-standing insulin-dependent diabetes mellitus. Acta Diabetol 36:73–76PubMedGoogle Scholar
  105. 105.
    Jermendy G (2006) Evaluating thiamine deficiency in patients with diabetes. Diab Vasc Dis Res 3:120–121PubMedGoogle Scholar
  106. 106.
    Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, Ahmed A, Rayman G, Bodmer CW (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 50:2164–2170PubMedGoogle Scholar
  107. 107.
    Stepuro II, Piletskaya TP, Stepuro VI, Maskevich SA (1997) Thiamine oxidative transformations catalyzed by copper ions and ascorbic acid. Biochemistry 62:1409–1414PubMedGoogle Scholar
  108. 108.
    Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064–2071PubMedGoogle Scholar
  109. 109.
    Arora S, Lidor A, Abularrage CJ, Weiswasser JM, Nylen E, Kellicut D, Sidawy AN (2006) Thiamine (vitamin B1) improves endothelium-dependent vasodilatation in the presence of hyperglycemia. Ann Vasc Surg 20:653–658PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Elena Beltramo
    • 1
  • Elena Berrone
    • 1
  • Sonia Tarallo
    • 1
  • Massimo Porta
    • 1
  1. 1.Department of Internal MedicineUniversity of TurinTurinItaly

Personalised recommendations